Autonomix Medical is skyrocketing Tuesday after securing U.S. Patent No. 12,433,670, expanding protection for its nerve-mapping platform.
Autonomix secures U.S. Patent 12,433,670 for nerve-mapping targeting seven cancer types; AMIX surges 386%. Proprietary medtech platform expands moat in neural signal processing—signals consolidation in precision medicine stack for healthcare AI investments.
Autonomix Medical Inc.
(NASDAQ:AMIX) shares are skyrocketing Tuesday afternoon after securing U.S.
Patent No. 12,433,670.
Titled "Systems and Methods for Treating Cancer and/or Augmenting Organ Function," the newly issued grant expands protection for the company’s minimally invasive nerve-mapping and targeting platform.
Autonomix Medical stock is among today's top performers.
Autonomix Medical shares surge 117% after hours following a $4.9 million warrant inducement deal.
Autonomix Medical shares surged 54.36% after hours, reversing an intraday decline after the company disclosed warrant…
Shares of Jupiter Neurosciences are surging Friday morning after partner PharmAla Biotech announced a series of corporate updates.
Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma…
Mobix Labs, Inc. (NASDAQ:MOBX) shares are trading higher Thursday after signing a binding Letter of Intent to acquire Vision…
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963…
Medical Test Name Explodes To A High After Earnings
Amgen Boosts Sales View By $1 Billion After Smashing Views
Fresh data backs Amplia push against pancreatic, ovarian cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
